Evidence for Malaria Medicines Policy. ACTwatch Study Reference Document Private-Sector Fever Case Management Study Uganda 2015
|
|
- Silvia Allen
- 6 years ago
- Views:
Transcription
1 Evidence for Malaria Medicines Policy ACTwatch Study Reference Document Private-Sector Fever Case Management Study Uganda 2015
2 Released August 16, 2016 Suggested citation ACTwatch Group and PACE. (2016). ACTwatch Study Reference Document: Uganda Private-Sector Fever Case Management Study Washington DC: PSI. Contact Dr. Megan Littrell ACTwatch Principal Investigator PSI th St NW Suit 600 Washington DC Peter Buyungo Programme for Aaccessible Communication and Education (PACE) Uganda Plot # 2, Ibis Vale, Kololo off Prince Charles Drive Kampala, Uganda pbugungo@pace.org.ug Acknowledgements ACTwatch is funded by the Bill and Melinda Gates Foundation, UNITAID, and the UK Department for International Development. This study was implemented by Population Services International (PSI). PACE Uganda Peter Buyungo Henry Kaula Doreen Nakimuli Ministry of Health Dr. Peter Okui ACTwatch Team Andrew Andrada Erick Auko Dr. Katie Bates Dr. Desmond Chavasse Kevin Duff Keith Esch Anna Fulton Tarryn Haslam Catharine Hurley Dr. Beth Kangwana Gloria Kigo Dr. Megan Littrell Julius Ngigi Dr. Kate O Connell Ricki Orford Stephen Poyer Dr. Justin Rahariniaina Christina Riley Dr. Andria Rusk Julianna Smith Rachel Thompson Cynthia Whitman Socio-Economic Data Center LTD (SEDC) Prof. Asingwire Narathius Joseph Kiwanuka Dr. Denis Muhangi SEDC (cont.) Dr. Janestic Twikirize Hadijah Mwenyango Sharlotte Tusasirwe Aloysious Nyombi Jacob Mutazidwa Team Leaders Tamali Adiru Robert Muwanguzi Joseph Jjumba Susan Akol Anibaya Rose Namugerwa George Basalirwa Suzan Nakkazi Fredrick Kabogoza Albert Gayi Bonita Nyamwire Team Members Juliet Donna Eyokia Creda Canongio Brian Mugenyi Annet Nnabunya Charlotte Kubahika Rogers Niwamanya Eria Paulo Ogwang Josephine Imaju Eliya Sabiiti Phionah Kamwine Rabson Masereka Moreen Mwamula Agnes Kateme Sam Meya Michael Paul Okumu Boniface Okello Robert Okello Team Members (cont.) Mary Christabel Etap Evans Arinda Patricia Namugenyi Julius Kankiriho Samuel Kakooza Fredrick Sserubuga Jimmy Opoka Page 1
3 Table of Contents LIST OF TABLES... 3 LIST OF FIGURES... 4 DEFINITIONS... 6 INTRODUCTION... 8 SUMMARY OF METHODS AND DATA COLLECTION... 9 SUMMARY OF KEY FINDINGS TABLES ANNEX 1: ACTWATCH BACKGROUND ANNEX 2: COUNTRY BACKGROUND ANNEX 4: SAMPLED SUB-COUNTIES ANNEX 3: FEVER CASE MANAGEMENT SURVEY METHODS ANNEX 5: QUESTIONNAIRE ANNEX 6: SAMPLING WEIGHTS ANNEX 7: INDICATOR DEFINITIONS Page 2
4 List of Tables Table 1: Description of outlets* Table 2: Description of fever patients*, by patient age and outlet type Table 3: Malaria blood testing, by patient age and outlet type Table 4: Positive malaria blood test result* among patients tested for malaria, by patient age and outlet type Table 5: Fever treatment by malaria test result, patient age and outlet type Table 6: Patient comprehension of malaria diagnostic testing Table 7: Factors associated with malaria blood testing Table 8: Factors associated with QA ACT treatment, among fever patients with confirmed malaria Table X1. Sampled Sub-Counties Page 3
5 List of Figures Figure 1: Diagram for outlet inclusion in the Fever CM study, Uganda, Figure 2: Diagram for patient inclusion in the Fever CM study, Uganda, Figure 3. Percentage of patients present at the outlet, across patient age Figure 4. Percentage of patients present at the outlet, across outlet type Figure 5. Percentage of patients who sought previous treatment for the current illness at a different source of care, across patient age Figure 6. Percentage of patients who sought previous treatment for the current illness at a different source of care, across outlet type Figure 7. Percentage of patients who reported receiving previous malaria testing and treatment for the current illness at a different source of care, across patient age Figure 8. Percentage of patients who reported receiving previous malaria testing and treatment for the current illness at a different source of care, across outlet type Figure 9. Percentage of patients who received a malaria blood test, across patient age Figure 10. Percentage of patients who received a malaria blood test, across outlet type Figure 11. Percentage of patients who received a malaria blood test, across patient age Figure 12. Percentage of patients who received a malaria blood test, across outlet type Figure 13. Percentage of patients who tested positive for malaria, among tested patients, across patient age Figure 14. Percentage of patients who tested positive for malaria, among tested patients, across outlet type Figure 15. Treatments received by patients who tested positive for malaria, across patient age Figure 16. Treatments received by patients who tested positive for malaria, across outlet type Figure 17. Treatments received by patients who tested negative for malaria, across patient age Figure 18. Treatments received by patients who tested negative for malaria, across outlet type Figure 19. Treatments received by patients who were not tested for malaria, across patient age Figure 20. Treatments received by patients who were not tested for malaria, across outlet type Page 4
6 Acronyms ACT AETD AL AMFm ASAQ BMGF CHW DHA PPQ DHS EMA GFATM iccm MOH NGO NMCP Oral AMT PMI Pf QA ACT mrdt SP UK USAID VHT WHO Artemisinin combination therapy Adult equivalent treatment dose Artemether lumefantrine Affordable Medicines Facility malaria Artesunate amodiaquine The Bill and Melinda Gates Foundation Community Health Worker Dihydroartemisinin piperaquine The Demographic and Health Survey European Medicines Agency Global Fund to Fight AIDS, TB, and Malaria Integrated community case management Ministry of Health Non-governmental Organization National Malaria Control Program Oral artemisinin monotherapy President s Malaria Initiative Plasmodium falciparum Quality-assured artemisinin combination therapy Malaria rapid diagnostic test Sulfadoxine Pyrimethamine United Kingdom United States Agency for International Development Village Health Team World Health Organization Page 5
7 Definitions Survey Methods Definitions Outlet Outlet survey Cluster Outlets eligible for inclusion in the Fever CM study Patients eligible for inclusion in the Fever CM study Consultation observation Patient exit interview Provider interview Any service delivery point or point of sale for commodities. Outlets are not restricted to stationary points of sale and may include mobile units or individuals. The Fever CM study was conducted as part of the 2015 national ACTwatch outlet survey. The outlet survey included a census of all public- and private-sector outlets with the potential to distribute antimalarials within a nationally representative sample of sub-counties. Outlets with antimalarials and/or malaria testing (malaria rapid diagnostic test or microscopy) in stock on the day of the survey or within the past three months were eligible for interview. The interview included an audit/inventory of all available antimalarials and malaria tests, as well as provider questions to assess malaria case management knowledge. The primary sampling unit, or cluster, for the outlet and Fever CM surveys. It is an administrative unit that hosts a population size of approximately 10,000 to 15,000 inhabitants. These units are defined by political boundaries. In Uganda, these were defined as sub-counties Outlets were eligible for the Fever CM study if they met the following criteria: 1) Private forprofit health facility, pharmacy, or drug store; 2) First-line artemisinin combination therapy (ACT) artemether lumefrantrine (AL) in stock on the day of the outlet survey; and 3) malaria blood testing available on the day of the outlet survey (mrdt or microscopy). Patients were eligible for the Fever CM study if they met the following criteria: 1) Respondent age 18 or older, 2) Patient at least 2 months of age, 3) Illness that includes fever or history of fever, 4) Presenting for treatment for this illness at this outlet for the first time, 5) Uncomplicated illness (not severe or life threatening), 6) Not currently pregnant, 7) Provides consent to participate in the study. A structured observation checklist was completed by an interviewer observing the interactions that the patient had with providers as she/he was provided with services at the outlet. The observation was concerned primarily with provider behaviors, including assessment, proper mrdt administration, and counseling for treatment with ACT. A brief exit interview was conducted with the patient after the patient visit was complete. The exit interview was concerned with capturing information about all medicines prescribed/obtained, and assessing patient understanding of the test result(s), diagnosis, and medication regimens prescribed. A brief series of questions was administered to providers to assess demographic characteristics, qualifications, training, and knowledge of the first-line treatment. Malaria Product Indicator Definitions Antimalarial Dosing/treatment regimen Artemisinin and its derivatives Artemisininbased Any medicine recognized by the World Health Organization (WHO) for the treatment of malaria. Medicines used solely for the prevention of malaria were excluded from analysis of key indicators in this report. The posology or timing and number of doses of an antimalarial used to treat malaria. This schedule often varies by patient weight. Artemisinin is a plant extract or synthetic plant extract used in the treatment of malaria. The most common derivatives of artemisinin used to treat malaria are artemether, artesunate, and dihydroartemisinin. An antimalarial that combines artemisinin or one of its derivatives with an antimalarial or antimalarials of a different class. Page 6
8 Combination Therapy (ACT) Non-artemisinin therapy First-line treatment Quality-assured Artemisinin- Based Combination Therapies (QA ACTs) An antimalarial medicine that does not contain artemisinin or any of its derivatives. The government-recommended treatment for uncomplicated malaria. Uganda s first-line treatment is artemether-lumefantrine. QA ACTs are ACTs that comply with the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) s Quality Assurance Policy. A QA ACT is any ACT that appeared on GFATM s indicative list of antimalarials meeting GFATM s quality assurance policy prior to data collection (see or that previously had C- status in an earlier GFATM quality assurance policy. QA ACTs also include ACTs that have been granted regulatory approval by the European Medicines Agency (EMA) specifically Eurartesim and Pyramax. Page 7
9 Introduction This reference document is a detailed presentation of the 2015 national ACTwatch Fever Case Management (Fever CM) study conducted in Uganda. The 2015 study was completed as part of the national ACTwatch outlet survey. The 2015 outlet survey followed previous survey rounds conducted by ACTwatch in Uganda in 2010, 2011, 2013, and Outlet survey findings from Uganda are available at ACTwatch is a multi-country research project implemented by PSI ( Standardized tools and approaches are employed to provide comparable data across countries and over time. ACTwatch is designed to provide timely, relevant, and high-quality antimalarial market evidence. The goal of providing this market evidence is to inform and monitor national and global policy, strategy, and funding decisions for improving malaria case management. The project was launched in 2008 with funding from the Bill and Melinda Gates Foundation (BMGF), and is currently funded through 2016 by the BMGF, UNITAID, and DFID. See Annex 1 for more information about the ACTwatch project. Recent efforts to improve malaria case management have focused on improving access to two key commodities: 1) malaria rapid diagnostic tests (mrdt) for confirmatory testing before treatment and 2) artemisinin-based combination therapy (ACT effective treatment for P. falciparum malaria). There is now evidence in Uganda that availability of malaria blood testing and quality-assured ACT have improved dramatically in recent years. However, due to the complexities of measuring malaria case management outcomes, there is less information available on the extent to which improved access to malaria rapid diagnostic tests (mrdts) and ACTs is facilitating consistent, appropriate management of suspected malaria cases. In other words, are available mrdts consistently used to confirm all suspected malaria cases, and are ACTs administered to confirmed cases only? Following on the significant investments made to improve access to malaria diagnostics and treatment, there is a need to document the uptake of these tools. This includes uptake of mrdts and ACT within sources of care that are frequently accessed by people seeking fever treatment. In Uganda, private providers at private for-profit health facilities, drug shops, and pharmacies are commonly accessed for fever care, and yet information on management of cases is typically not tracked in any systematic way. Health provider behavior is complex, and multiple factors influence case management practices and outcomes. As compared with the more highly regulated and supervised public health sector, the set of factors influencing case management outcomes may be particularly complex and yet not welldocumented in the private sector. The Fever CM study documents key aspects of the interactions between private-sector providers and clients seeking fever treatment, including two case management outcomes: 1) confirmatory malaria blood testing and 2) appropriate treatment according to test result. This research complements available evidence currently used to track progress in malaria case management. The ACTwatch outlet surveys track trends in mrdt and antimalarial availability, price, and market share. The Fever CM research component documents the extent to which recent and current efforts to improve availability of key malaria commodities are sufficient for facilitating appropriate management of suspected malaria cases. This research will provide information to inform interventions designed to close gaps between availability of quality-assured malaria diagnostics and medicines and their routine use in managing clients. Report notes This document is a complete reference for the 2015 Fever CM survey. Please see annexes for information about the study context, design, implementation, and data analysis. Grey text for data appearing in report tables indicates that the estimate provided was derived from a small sample size. Specifically, grey text is used to indicate point estimates derived from an n of less than 50. Results are presented for children under five and people age five and older. The total patient estimates include n=6 patients for which patient age was missing. Page 8
10 Summary of Methods and Data Collection National Outlet Survey A representative antimalarial outlet survey was conducted at the national level in Uganda between May 19 and July 2, A full description of research design and methods is provided in the Uganda Outlet Survey Reference Document available at Briefly, a representative sample of sub-counties was selected from urban and rural domains (see Annex 3). Within selected clusters, a census of all outlets with the potential to sell or distribute antimalarials and/or provide malaria blood testing was completed. Outlets were screened to determine eligibility. Outlets eligible for the survey met at least one of three criteria: 1) one or more antimalarials were in stock on the day of the survey, 2) one or more antimalarials were in stock in the three months preceding the survey, and/or 3) malaria blood testing (microscopy or RDT) was available. A structured questionnaire was used to complete an audit of all antimalarials and RDTs as well as a provider interview. Fever Case Management Survey Private-sector outlets meeting eligibility criteria for the Fever CM survey were identified during the outlet survey and revisited for Fever CM data collection. Eligibility criteria for the Fever CM survey component were as follows: 1) private for-profit health facility, pharmacy, or drug store; 2) national first-line ACT, artemether lumefantrine (AL), in stock on the day of the outlet survey; and 3) malaria blood testing (mrdt or microscopy) available on the day of the outlet survey. Fieldworkers dedicated to the Fever CM study revisited eligible outlets identified during the outlet survey and completed patient screening for a maximum of one day. All patients visiting eligible outlets were screened to determine eligibility for the study. Clients were invited to participate in the study if they met the following eligibility criteria: Respondent age 18 or older Patient at least 2 months of age Illness that includes fever or history of fever Presenting for treatment for this illness at this outlet for the first time Uncomplicated illness (not severe or life threatening) Not currently pregnant Provides consent to participate in the study Following informed consent procedures, a structured observation checklist was completed by an interviewer observing the interactions that the patient had with providers as she/he was provided with services at the outlet. The observation was concerned primarily with provider behaviors, including assessment, proper RDT administration, and counseling for treatment with ACT. After the patient visit was complete, a brief exit interview was administered with the patient. The exit interview was concerned with capturing information about all medicines prescribed/obtained, and assessing patient understanding of the test result(s), diagnosis, and medication regimens prescribed. Full details of survey methodology are available in Annex 4 and the Fever CM questionnaire is available in Annex 5. Double data entry was completed using Microsoft Access. All data cleaning and analysis was performed using Stata 13.1 ( StataCorp, College Station, TX). Data were weighted to account for variation in probability of outlet selection (see Annex 6), and standard error calculation reflected clustering of outlets at commune level. Standard indicators were constructed according to definitions applied across ACTwatch project countries (see Annex 7). Page 9
11 Figure 1: Diagram for outlet inclusion in the Fever CM study, Uganda, 2015 A Eligible outlets* [1,266] B Outlets visited for the Fever CM study** [1,146] C Outlets that participated in patient screening*** [1,089] Eligible outlets that were not revisited for the Fever CM study ** [120] Outlets that did not participate in patient screening [57] Provider refused [32] Outlet closed [17] No patients during study period [8] Outlets with no eligible patients [259] Outlet Type Outlet Location D Outlets with completed patient observation and exit interviews [830] Private For-Profit Health Facility Pharmacy Drug Store Urban Rural * Outlets identified during the national outlet survey that met the following criteria: 1) Pharmacy, drug store, or private for-profit health facility including hospitals and clinics; 2) ACT in stock on the day of the outlet survey; 3) malaria testing available on the day of the survey (malaria RDT and/or microscopy). ** 120 eligible outlets were not flagged during the outlet survey as eligible for the Fever Case Management component and therefore were not included in the study. *** Patient screening was conducted for a maximum of one day or until patient observation and exit interviews were completed for one eligible child under age 5 and one eligible person age 5 and older. Page 10
12 Figure 2: Diagram for patient inclusion in the Fever CM study, Uganda, 2015 A Patients screened* [9,330] Respondent under 18 [574] No fever [6,321] Patients without completed observation and exit interview [8,057] Follow-up visit to same outlet [597] Infant < 2 months [19] Pregnant [101] Severe illness [52] Refusal [389] Completed observation only [4] Patient Age 49 Patient Sex 1 B Patients with completed observation and exit interview [1,273] years 5-14 years years 50+ years Unknown Male Female Unknown * Patients were screened when they first approached an outlet to determine eligibility for the Fever CM component. Eligibility criteria were as follows: Respondent at least 18 years of age (patient or patient s caregiver), seeking treatment for fever, seeking treatment for the first time for the current illness at this outlet, at least 2 months of age, not reportedly pregnant, and no signs or referral for severe illness for this illness. 389 patients refused to participate, and 4 were observed but refused to complete the exit interview. Page 11
13 Summary of Key Findings Figure 3. Percentage of patients present at the outlet, across patient age Among all patients with completed consultation observation and exit interviews Age 0-4 Age 5+ All Patients Patient present at the outlet Patient not present (family/friend seeking treatment) N=545 N=722 N= of patients that were included in the study were present at the outlet at the time of the consultation observation and exit interview. The remaining 26 were not present and care was being sought on the patient s behalf by a family member or friend. The percentage of patients present during the consultation was higher for people age five and above (80) as compared to children under five (68). Page 12
14 Figure 4. Percentage of patients present at the outlet, across outlet type Among all patients with completed consultation observation and exit interviews Private For-Profit Health Facilities Pharmacies Drug Stores Patient present at the outlet 15 Patient not present (family/friend seeking treatment) N=630 N=219 N=424 The percentage of patients present during the consultation was highest for patients seeking care at private for-profit health facilities (85), and relatively lower among patients seeking care at pharmacies (49) and drug stores (65). Among patients seeking care at each outlet type, children under five were consistently less likely to be present at the consultation as compared with people age five and above (see Table 2). Page 13
15 PERCENT OF PATIENTS Figure 5. Percentage of patients who sought previous treatment for the current illness at a different source of care, across patient age Among all patients with completed consultation observation and exit interviews About one-quarter of all patients seeking fever treatment reported seeking treatment at another source of care prior to study visit (23). Previous treatment seeking was reported in the public sector among 10 of patients and in the private sector among 14 of patients. Levels of previous treatment seeking were similar among children under five as compared with people age five and older. PERCENT OF PATIENTS Sought Previous Treatment Sought Previous Treatment - Public Sector Age 0-4 Age 5+ All Patients Sought Previous Treatment - Private Sector Figure 6. Percentage of patients who sought previous treatment for the current illness at a different source of care, across outlet type Among all patients with completed consultation observation and exit interviews Sought Previous Treatment Sought Previous Treatment - Public Sector Sought Previous Treatment - Private Sector Private For-Profit Facilities Pharmacies Drug Stores More than one-third of patients seeking care at pharmacies reported seeking previous treatment for the current illness (38), as compared with one-quarter (25) of patients seeking care at drug stores and 21 of patients seeking care at private for-profit facilities. Previous treatment-seeking in the public sector was more common among patients seeking care at pharmacies (18) and drug stores (13), as compared with patients seeking care at private facilities (6). Page 14
16 PERCENT OF PATIENTS Figure 7. Percentage of patients who reported receiving previous malaria testing and treatment for the current illness at a different source of care, across patient age Among all patients with completed consultation observation and exit interviews Reported Previous Malaria Test Reported Previous Malaria Treatment 9 of patients reported receiving a malaria blood test and 13 reported receiving antimalarial treatment from another source of care prior to the study visit. Previous malaria testing and treatment was similar among children under five and people age five and older. PERCENT OF PATIENTS Figure 8. Percentage of patients who reported receiving previous malaria testing and treatment for the current illness at a different source of care, across outlet type Among all patients with completed consultation observation and exit interviews Reported Previous Malaria Test Age 0-4 Age 5+ All Patients Reported Previous Malaria Treatment Private For-Profit Facilities Pharmacies Drug Stores One-quarter (26) of patients seeking care at pharmacies reported receiving a malaria blood test at another source of care prior to the study visit, as compared with 10 of patients seeking care at drug stores and 7 of patients seeking care at private for-profit facilities. Data trends suggest higher reports of previous antimalarial treatment received among patients seeking care at drug stores (13) and private for-profit health facilities (13) compared with patients seeking care at pharmacies (7). Page 15
17 Figure 9. Percentage of patients who received a malaria blood test, across patient age Among all patients with completed consultation observation and exit interviews, including patients present and not present during the consult Received a malaria blood test - mrdt Age 0-4 Age 5+ All Patients Received a malaria blood test - mrdt & microscopy Received a malaria blood test - microscopy Present, did not receive a malaria test Not present (did not receive a malaria test) N= N= N= of all fever patients received a malaria blood test. Testing was similar among children younger than five (43) and people age five and older (46). The majority of patients tested for malaria were tested using mrdts. Among all fever patients, 31 were tested by mrdt and 15.5 were tested by malaria microscopy. 2 of patients were tested by both mrdt and microscopy. Nearly one-third of all patients were present at the outlet but did not receive a malaria blood test (30). Among children younger than five, 25 were present at the outlet and not tested compared with 35 of people age five and older. In nearly one in ten cases (9), the provider recommended a blood test but the patient or caregiver refused the test (see Table 3). Page 16
18 Figure 10. Percentage of patients who received a malaria blood test, across outlet type Among all patients with completed consultation observation and exit interviews, including patients present and not present during the consult Received a malaria blood test - mrdt Private For-Profit Health Facilities 0 Pharmacies Drug Stores Received a malaria blood test - mrdt & microscopy Received a malaria blood test - microscopy Present, did not receive a malaria test Not present (did not receive a malaria test) N= N= N= of all patients seeking care at private for-profit health facilities received a malaria blood test, as compared with 30 at drug stores and 1.5 at pharmacies. At private health facilities, testing by mrdt and microscopy were frequently observed. A total of 36 of patients at private facilities were tested by mrdts and 32 by malaria microscopy. 5 of patients were tested by both mrdt and malaria microscopy. Nearly all testing performed at drug stores was by mrdt. Among patients seeking care at private facilities, 22 were present but did not receive a test. A higher percentage of patients were present but not tested at drug stores (35) and pharmacies (42). At private facilities, only 15 of patients were not present at the consult (and therefore could not be tested). This compares with nearly half of patients at pharmacies (45) and one-third at drug stores (35). A provider recommended a blood test but the patient or caregiver refused the test for 8 of patients at private facilities, as compared with 10 at drug stores and only 3 at pharmacies (see Table 3). Page 17
19 Figure 11. Percentage of patients who received a malaria blood test, across patient age Among all patients present during the completed consultation observation and exit interview PERCENT OF PATIENTS Age 0-4 Age 5+ All Patients Among patients who were present during the consultation, 60 received a malaria blood test. Data trends suggest that testing was more common among children younger than five (64) compared to patients age five and older (57). PERCENT OF PATIENTS Figure 12. Percentage of patients who received a malaria blood test, across outlet type Among all patients present during the completed consultation observation and exit interview Private For-Profit Facilities Pharmacies Drug Stores Among patients who were present during the consultation, 74 who were managed at private for-profit health facilities received a malaria blood test, as compared with 46 at drug stores and only 3 at pharmacies. Page 18
20 Figure 13. Percentage of patients who tested positive for malaria, among tested patients, across patient age Among all patients with completed consultation observation and exit interviews PERCENT OF PATIENTS Age 0-4 Age 5+ All Patients Among patients who were tested for malaria, 59 had a positive test result. The percentage of patients who tested positive for malaria was similar among children younger than five (59) and people age five and older (58). Figure 14. Percentage of patients who tested positive for malaria, among tested patients, across outlet type Among all patients with completed consultation observation and exit interviews PERCENT OF PATIENTS Private For-Profit Facilities Pharmacies Drug Stores Among patients who were tested for malaria, data trends suggest a higher percentage of patients at drug stores tested positive (68), as compared with patients in private for-profit health facilities (54) and pharmacies (54). Page 19
21 PERCENT OF PATIENTS Figure 15. Treatments received by patients who tested positive for malaria, across patient age Among all patients with completed consultation observation and exit interviews Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Non-Artemisinin Therapy Age 0-4 Age 5+ All Patients Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Among patients who tested positive for malaria (N=266), 83 received antimalarial treatment. 60 received treatment with an ACT: 49 with a quality-assured ACT (ACT from a manufacturer with WHO pre-qualification or GFATM procurement approval) and 12 with a non-quality-assured ACT. 14 of all patients who tested positive received treatment with a non-artemisinin therapy. Non-artemisinin therapies received were primarily quinine injections, tablets, and syrups, as well as Sulfadoxine Pyrimethamine (SP) tablets and a few chloroquine tablet treatments. 15 of all positive patients received an artemisinin monotherapy, and these were primarily artemether injections (indicated for the treatment of severe malaria cases). Antibiotics were received by 43 of positive patients. These included amoxicillin, ampicillin, erythromycin, sulfamethoxazole and trimethoprim tablets and suspensions, metronidazole and ciprofloxacin tablets, and a variety of other antibiotics. The majority of patients were treated with a pain- or fever-reducing medication (79), such as acetaminophen (paracetamol), ibruprofen, or diclofenac. Among patients who tested positive for malaria and did not receive an antimalarial, a small percentage (14) reported receiving an antimalarial at another source, and 1 received a prescription for an antimalarial to be filled at another source of care (data not shown). Treatment of patients who tested positive for malaria was generally similar for children younger than five compared with people age five and older. Data trends suggest slightly higher antimalarial treatment for people age five and older (88) compared to children younger than five (81). 16 of people age five and older received a non-quality-assured ACT compared with 9 of children younger than five. However, data trends suggest that children younger than five were more likely to receive artemisinin monotherapy (19) compared with people age five and older (12). Page 20
22 PERCENT OF PATIENTS Figure 16. Treatments received by patients who tested positive for malaria, across outlet type Among all patients with completed consultation observation and exit interviews Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Private For-Profit Health Facilities Non-Artemisinin Therapy Drug Stores Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Among patients who tested positive for malaria at private for-profit health facilities (N=188), 74 received antimalarial treatment. Among positive patients at drug stores (N=75), nearly all (97) received antimalarial treatment. Only N=3 patients tested positive at pharmacies and are not shown here (see Table 5). Positive patients at drug stores were more likely to receive ACT treatment compared with patients at private facilities, including any ACT (78 versus 49) and qualityassured ACT (68 versus 49). Data trends suggest that artemisinin monotherapies (injectables) were more commonly received by patients at private facilities (20) compared with drug stores (7). Data trends suggest that antibiotics were more commonly received by positive patients at private facilities (47) compared with patients at drug stores (35), as well as that pain- and fever-reducing medications were more commonly received at drug stores (88) compared with private facilities (73). Page 21
23 PERCENT OF PATIENTS Figure 17. Treatments received by patients who tested negative for malaria, across patient age Among all patients with completed consultation observation and exit interviews Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Non-Artemisinin Therapy Age 0-4 Age 5+ All Patients Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Among patients who tested negative for malaria (N=250), 14 received antimalarial treatment. 10 received treatment with an ACT, and 4 received treatment with a non-artemisinin therapy (primarily SP). Antibiotics were received by 55 of negative patients. These included amoxicillin, ampicillin, erythromycin, sulfamethoxazole and trimethoprim tablets and suspensions, metronidazole and ciprofloxacin tablets, and a variety of other antibiotics. More than half of patients were treated with a pain- or fever-reducing medication (61), such as acetaminophen (paracetamol), ibruprofen, or diclofenac. Data trends suggest higher antimalarial treatment for negative children younger than five (19) compared to people age five and older (10). This included 15 of negative children younger than five who received an ACT compared with 6 of people age five and older. Data trends also suggest that non-antimalarial treatment was higher among children younger than five compared with people age five and older, including antibiotic treatment (62 versus 49) and treatment with pain- and fever-reducing medicines (69 versus 55). Page 22
24 PERCENT OF PATIENTS Figure 18. Treatments received by patients who tested negative for malaria, across outlet type Among all patients with completed consultation observation and exit interviews Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Private For-Profit Health Facilities Non-Artemisinin Therapy Drug Stores Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Among patients who tested negative for malaria at private for-profit health facilities (N=196), 12 received antimalarial treatment. Among negative patients at drug stores (N=50), 22 received antimalarial treatment. Only N=4 patients tested negative within pharmacies and are not shown here (see Table 5). Data trends suggest that negative patients at drug stores were more likely to receive ACT treatment (18) compared with patients at private facilities (8). Data trends suggest that antibiotics were more commonly received by negative patients at drug stores (65) compared with patients at private facilities (51), as well as that pain- and fever-reducing medications were more commonly received at private facilities (72) compared with drug stores (58). Page 23
25 PERCENT OF PATIENTS Figure 19. Treatments received by patients who were not tested for malaria, across patient age Among all patients with completed consultation observation and exit interviews Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Non-Artemisinin Therapy Age 0-4 Age 5+ All Patients Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Among patients who were not tested for malaria (N=753), 51 received antimalarial treatment. 43 received treatment with an ACT: 34 with a quality-assured ACT (ACT from a manufacturer with WHO pre-qualification or GFATM procurement approval) and 9 with a non-quality-assured ACT. 8 of all patients who were not tested for malaria received treatment with a non-artemisinin therapy. Non-artemisinin therapies received were primarily quinine injections, tablets, and syrups, as well as SP tablets and a few chloroquine tablet treatments. Antibiotics were received by 24 of patients who were not tested for malaria. These included amoxicillin, ampicillin, erythromycin, sulfamethoxazole and trimethoprim tablets and suspensions, metronidazole and ciprofloxacin tablets, and a variety of other antibiotics. The majority of patients were treated with a pain- or fever-reducing medication (65), such as acetaminophen (paracetamol), ibruprofen, or diclofenac. Treatment of patients who were not tested for malaria was generally similar for children younger than five compared with people age five and older. Data trends suggest slightly higher antimalarial treatment for people age five and older (54) compared to children younger than five (47). 45 of people age five and older received a non-quality-assured ACT compared with 39 of children younger than five. Page 24
26 Figure 20. Treatments received by patients who were not tested for malaria, across outlet type Among all patients with completed consultation observation and exit interviews PERCENT OF PATIENTS Any Antimalarial Any ACT Quality-Assured ACT Non-Quality-Assured ACT Non-Artemisinin Therapy Artemisinin Monotherapy Any Antibiotic Any Pain/Fever Reducer Private For-Profit Health Facilities Pharmacies Drug Stores Among patients who were not tested for malaria at private for-profit health facilities (N=244), 43 received antimalarial treatment. Data trends suggest that antimalarial treatment was higher for patients who were not tested at pharmacies (N=212, 55) and drug stores (N=297, 54). Treatment with non-qualityassured ACTs was higher at pharmacies (18), as compared with private facilities (5) and drug stores (10). Data trends suggest higher treatment with qualityassured ACTs at private facilities (32) and drug stores (36), as compared with pharamcies (25). Antibiotic treatment for people who were not tested for malaria was similar across outlet types. Data trends suggest higher treatment with pain- and feverreducing medications among patients seeking care at drug stores (67), as compared with pharmacies (56) and private facilities (61). Page 25
27 Factors associated with malaria blood testing and quality-assured ACT treatment for confirmed cases Logistic regression was used to test for association between outlet, patient, and provider characteristics and two outcomes: 1) malaria blood testing for all fever patients and 2) quality-assured ACT treatment for confirmed cases. Factors with a significant association with malaria testing included (see Table 7): Outlet type: patients at drug stores were 27.1 times more likely to receive a test compared with pharmacies, and patients at private for-profit health facilities were times more likely to receive a test compared to pharmacies. Patient report of fever during the consultation (prompted or unprompted): patients who reported fever to the provider were 3.8 times more likely to receive a test compared to patients who did not report fever. Previous testing: patients who were not previously tested for malaria for the current illness were 3.4 times more likely to be tested compared with patients who had previously received a malaria test. Factors that were not significantly associated with malaria testing included (see Table 7): Urban/rural location Patient sex Patient age Recent provider case management training Price of malaria testing (below median price versus median and above). Factors with a significant association with quality-assured ACT treatment, among confirmed cases, included (see Table 8): Outlet type: patients in drug stores were 3.9 times more likely to receive quality-assured ACT treatment compared with patients in private facilities. Price of quality-assured ACT treatment: patients within outlets where one adult equivalent treatment dose (AETD) of quality-assured ACT treatment was below median price were 1.6 times more likely to receive quality-assured ACT treatment, as compared with outlets where one AETD was the median price or higher. Factors that were not significantly associated with quality-assured ACT treatment included (see Table 8): Urban/rural location Patient sex Patient age Patient report of fever during the consultation (prompted or unprompted) Previous treatment-seeking and previous antimalarial treatment for the current illness Recent provider case management training Provider knowledge of the national first-line treatment Provider belief that ACT is most effective for malaria infection Page 26
28 Tables Table 1: Description of outlets* Private For-Profit Facility Pharmacy Drug Store All Outlets (95 CI) (95 CI) (95 CI) (95 CI) Proportion of outlets* N=423 N=147 N=260 N=830 Stocking malaria commodities on the day of the outlet survey First-line ACT (AL) Quality-assured ACT ( ) ( ) ( ) ( ) Non-artemisinin therapy ( ) - ( ) ( ) Any malaria test Malaria RDT ( ) - ( ) ( ) Malaria microscopy ( ) ( ) ( ) ( ) Provider training and knowledge** N=422 N=147 N=260 N=829 Reported receiving malaria CM training in the past year** (45.2, 60.3) (37.5, 72.1) (29.2, 44.4) (39.3, 50.4) Correctly cited the national first-line treatment for uncomplicated malaria (AL) (78.4, 89.6) (79.7, 93.5) (73.1, 86.2) (78.1, 86.6) Cited ACT as the most effective treatment for uncomplicated malaria in adults (82.5, 92.5) (86.9, 97.7) (80.0, 91.7) (83.5, 91.1) Cited ACT as the most effective treatment for uncomplicated malaria in children under five (76.5, 89.3) (70.6, 94.4) (80.0, 91.0) (80.4, 88.9) Cited ACT as the most effective treatment for uncomplicated malaria in children under five and adults (69.5, 84.3) (68.8, 91.5) (72.0, 86.8) (73.4, 84.1) * Outlets with one or two patients who completed observation and exit interview components. ** Outlet had 1 or more providers with specified training or knowledge seeing patients on the day of the Fever CM survey. *** Provider reported receiving training, including pre-service training or stand-alone workshops, on malaria diagnosis/malaria RDTs/malaria microscopy and/or treatment on the national malaria treatment guidelines. Source: ACTwatch Fever CM Survey, Uganda, Page 27
29 Table 2: Description of fever patients*, by patient age and outlet type Age 0-4 Age 5 and Above All Patients Proportion of fever patients*: (95 CI) (95 CI) (95 CI) All outlets N=545 N=722 N=1273 Present at consultation ( ) ( ) ( ) Reported fever symptoms to a provider during the consultation (prompted or unprompted) ( ) ( ) ( ) Prior to the current visit for this illness: N=544 N=722 N=1272 Sought treatment elsewhere for this illness ( ) ( ) ( ) Public (facility, CHW) ^ ( ) ( ) ( ) Private (formal or informal) ^ ( ) ( ) ( ) Received a malaria blood test ( ) ( ) ( ) Received any medicine ( ) ( ) ( ) Received an antimalarial ( ) ( ) ( ) Private For-Profit Health Facilities N=275 N=352 N=630 Present at consultation ( ) ( ) ( ) Reported fever symptoms to a provider during the consultation (prompted or unprompted) ( ) ( ) ( ) Prior to the current visit for this illness: Sought treatment elsewhere for this illness ( ) ( ) ( ) Public (facility, CHW) ^ ( ) ( ) ( ) Private (formal or informal) ^ ( ) ( ) ( ) Received a malaria blood test ( ) ( ) ( ) Received any medicine ( ) ( ) ( ) Received an antimalarial ( ) ( ) ( ) Pharmacy N=80 N=138 N=219 Present at consultation ( ) ( ) ( ) Reported fever symptoms to a provider during the consultation (prompted or unprompted) ( ) ( ) ( ) Prior to the current visit for this illness: Sought treatment elsewhere for this illness Public (facility, CHW) Private (formal or informal) Received a malaria blood test ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Page 28
30 Table 2: Description of fever patients*, by patient age and outlet type Age 0-4 Age 5 and Above All Patients Received any medicine ( ) ( ) ( ) Received an antimalarial ( ) ( ) ( ) Drug Store N=190 N=232 N=424 Present at consultation ( ) ( ) ( ) Reported fever symptoms to a provider during the consultation (prompted or unprompted) ( ) ( ) ( ) Prior to the current visit for this illness: Sought treatment elsewhere for this illness ( ) ( ) ( ) Public (facility, CHW) ^ ( ) ( ) ( ) Private (formal or informal) ^ ( ) ( ) ( ) Received a malaria blood test ( ) ( ) ( ) Received any medicine ( ) ( ) ( ) Received an antimalarial ( ) ( ) ( ) * Patients eligible for the Fever CM study with completed observation and exit interview components. ^ Specific source for previous treatment was reported as don t know for 5 individuals and was missing for 2 individuals; these observations were excluded from these indicators. This includes 2 observations excluded from drug stores and 5 observations excluded from private health facilities. Source: ACTwatch Fever CM Survey, Uganda, Page 29
31 Table 3: Malaria blood testing, by patient age and outlet type Age 0-4 Age 5 and Above All Patients Proportion of patients who received*: (95 CI) (95 CI) (95 CI) All outlets N=545 N=722 N=1,273 Any malaria test ( ) ( ) ( ) Malaria RDT ( ) ( ) ( ) Malaria microscopy ( ) ( ) ( ) Both malaria RDT and microscopy ( ) ( ) ( ) No malaria test, present at the outlet ( ) ( ) ( ) No malaria test, not present at the outlet # ( ) ( ) ( ) Provider recommendation to test but refused testing ( ) ( ) Private For-Profit Health Facilities N=275 N=352 N=630 Any malaria test ( ) ( ) ( ) Malaria RDT ( ) ( ) ( ) Malaria microscopy ( ) ( ) ( ) Both malaria RDT and microscopy ( ) ( ) ( ) No malaria test, present at the outlet ( ) ( ) ( ) No malaria test, not present at the outlet # ( ) ( ) ( ) Provider recommendation to test but refused testing ( ) ( ) ( ) Pharmacy N=80 N=138 N=219 Any malaria test ( ) ( ) ( ) Malaria RDT ( ) ( ) Malaria microscopy ( ) ( ) ( ) Both malaria RDT and microscopy No malaria test, present at the outlet ( ) ( ) ( ) No malaria test, not present at the outlet # ( ) ( ) ( ) Provider recommendation to test but refused testing ( ) ( ) ( ) Drug Store N=190 N=232 N=424 Any malaria test ( ) ( ) ( ) Malaria RDT ( ) ( ) ( ) Malaria microscopy ( ) ( ) ( ) Page 30
32 Table 3: Malaria blood testing, by patient age and outlet type Both malaria RDT and microscopy No malaria test, present at the outlet No malaria test, not present at the outlet # Provider recommendation to test but refused testing Age 0-4 Age 5 and Above All Patients ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) * Patients eligible for the Fever CM study with completed observation and exit interview components. # Patient was not present during the consult and care was sought on his/her behalf by a family member or friend. Source: ACTwatch Fever CM Survey, Uganda, Page 31
33 Table 4: Positive malaria blood test result* among patients tested for malaria, by patient age and outlet type Age 0-4 Age 5 and Above All Patients Proportion of patients who tested positive for malaria, among tested patients All outlets Private For-Profit Health Facilities Pharmacy Drug Store * Recorded during patient consultation observation. Source: ACTwatch Fever CM Survey, Uganda, (95 CI) (95 CI) (95 CI) N=231 N=284 N= ( ) ( ) ( ) N=175 N=208 N= ( ) ( ) ( ) N=2 N=5 N= ( ) ( ) ( ) N=54 N=71 N= ( ) ( ) ( ) Page 32
34 Table 5: Fever treatment by malaria test result, patient age and outlet type Malaria Test Positive Malaria Test Negative Not Tested Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Proportion of patients who received: (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) All outlets N=124 N=141 N=266 N=107 N=143 N=250 N=313 N=435 N=753 Any antimalarial ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Any ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Quality-assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Non-quality assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Non-artemisinin therapy * ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Artemisinin monotherapy ** ( ) ( ) ( ) ( ) - ( ) ( ) ( ) ( ) Antibiotic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Antipyretic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Prescription for antimalarial treatment to be filled elsewhere # (0.2, 1.6) - (0.1, 0.8) (0.2, 9.6) (0.7, 26.9) (0.7, 14.4) (0.1, 3.7) - (<0.1, 1.8) Private For-Profit Health Facilities N=91 N=96 N=188 N=84 N=112 N=196 N=99 N=143 N=244 Any antimalarial ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Any ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Quality-assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Page 33
35 Table 5: Fever treatment by malaria test result, patient age and outlet type Malaria Test Positive Malaria Test Negative Not Tested Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Proportion of patients who received: (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) Non-quality assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Non-artemisinin therapy * ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Artemisinin monotherapy ** ( ) ( ) ( ) ( ) - ( ) - (< ) (< ) Antibiotic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Antipyretic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Prescription for antimalarial treatment to be filled elsewhere # (0.3, 2.5) - (0.1, 1.2) (0.3, 13.6) (0.8, 31.9) (0.9, 18.3) Pharmacies N=1 N=2 N=3 N=1 N=3 N=4 N=78 N=133 N=212 Any antimalarial ( ) ( ) ( ) ( ) ( ) Any ACT ( ) ( ) - ( ) ( ) ( ) ( ) ( ) Quality-assured ACT ( ) - ( ) ( ) ( ) ( ) ( ) Non-quality assured ACT ( ) ( ) ( ) ( ) ( ) Non-artemisinin therapy * ( ) ( ) ( ) ( ) ( ) Artemisinin monotherapy ** ( ) ( ) - - ( ) ( ) (< ) ( ) Antibiotic ( ) ( ) - ( ) ( ) ( ) ( ) ( ) Antipyretic ( ) ( ) ( ) ( ) ( ) Page 34
36 Table 5: Fever treatment by malaria test result, patient age and outlet type Malaria Test Positive Malaria Test Negative Not Tested Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Age 0-4 Age 5 and Above All Patients Proportion of patients who received: (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) (95 CI) Prescription for antimalarial treatment to be filled elsewhere # Drug Stores N=32 N=43 N=75 N=22 N=28 N=50 N=136 N=159 N=297 Any antimalarial ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Any ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Quality-assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Non-quality assured ACT ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Non-artemisinin therapy * ( ) ( ) ( ) ( ) - ( ) ( ) ( ) ( ) Artemisinin monotherapy ** ( ) ( ) ( ) ( ) ( ) ( ) Antibiotic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Antipyretic ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Prescription for antimalarial treatment to be filled - (0.1, 2.7) ( ) elsewhere # * Primarily quinine injections, tablets, syrups as well as SP tablets and a few chloroquine tablet treatments. ** Primarily artemether injections. # Patient received a prescription for an antimalarial, but did not receive an antimalarial at the outlet (exiting without treatment). Prescriptions were written for antimalarials, including injectable artemether or artesunate, artemether lumefantrine, and quinine. Source: ACTwatch Fever CM Survey, Uganda, Page 35
37 Table 6: Patient comprehension of malaria diagnostic testing Proportion of fever patients who correctly recall whether or not a malaria test was performed during the consultation* All outlets Private For-Profit Health Facilities Pharmacy Drug Store Proportion of fever patients who correctly recall the malaria test result (positive, negative), among patients who were tested during the consultation** All outlets Private For-Profit Health Facilities Pharmacy Drug Store Age 0-4 Age 5 and Above All Patients (95 CI) (95 CI) (95 CI) N=545 N=720 N=1, ( ) ( ) N=275 N=351 N= N=80 N=137 N= N=190 N=232 N= ( ) ( ) N=231 N=286 N= ( ) ( ) ( ) N=175 N=209 N= ( ) ( ) ( ) N=2 N=5 N= N=54 N=72 N= ( ) ( ) ( ) * Among 520 tested, 519 reported testing. Among 753 not tested, 751 reported no testing and 2 responses were missing. Cases with missing responses were excluded from this table. ** Among 266 with a positive test, 262 reported a positive test, 2 reported a negative test, and 2 responded with don t know test result. Among 250 with a negative test, 245 reported a negative test, 2 reported a positive test, 1 responded with don t know test result, and 2 responses were missing. Cases with missing responses were excluded from this table. Source: ACTwatch Fever CM Survey, Uganda, Page 36
38 Table 7: Factors associated with malaria blood testing Tested Odds Ratio Proportion of patients tested, by patient and provider/outlet factors All patients Type of outlet Pharmacy Drug Store Private For-Profit Facility Outlet location Rural area Urban area Patient sex Male Female Patient age 50 years or older years 5-14 years 0-4 years Present at consultation Patient not present Patient present Reported fever symptoms to a provider during the consultation (prompted or unprompted) Did not report fever Reported fever Prior to the current visit for this illness: Sought treatment elsewhere for this illness Did not seek treatment elsewhere for this illness Received a malaria blood test Tested previously Not tested previously Received any medicine Treated previously N of Patients (95 CI) 1, ( ) OR (95 CI) ref ( ) *** ( ) ( ) *** ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ref ( ) ( ) ( ) ( ) ( ) ( ) ( ) ref ( ) ref ( ) 1, ** ( ) ( ) ref ( ) ( ) ( ) ref ( ) 1, ** ( ) ( ) ref ( ) Page 37
39 Table 7: Factors associated with malaria blood testing Not treated previously Received an antimalarial Treated previously Not treated previously Provider with recent malaria CM training # Untrained provider Trained provider Provider with correct first-line knowledge ## Provider without knowledge Provider with knowledge Provider who cites ACT as most effective ### Provider without knowledge Provider with knowledge Price of malaria testing ^ Median and above Below median price * p<0.05 ** p<0.01 ***p<0.001 Tested Odds Ratio 1, ( ) ( ) ref ( ) 1, ( ) ( ) ref ( ) ( ) ( ) ref ( ) 1, ( ) ( ) ref ( ) 1, ( ) ( ) ref ( ) ( ) ( ) # Provider reported receiving training, including pre-service training or stand-alone workshops, on malaria diagnosis/malaria RDTs/malaria microscopy and/or treatment on the national malaria treatment guidelines. ## Provider correctly cited the national first-line treatment for uncomplicated malaria (AL). ### Provider named ACT as the most effective treatment for malaria in children younger than five and adults. ^ Price for the least expensive testing option for an adult (RDT or microscopy) available at the outlet on the day of the survey. A median was calculated across all outlets, and outlets were classified as providing testing that was at median cost or above, or below the median. Price for testing was not available for 21 patients. Source: ACTwatch Fever CM Survey, Uganda, Page 38
40 Table 8: Factors associated with QA ACT treatment, among fever patients with confirmed malaria Treated with QA ACT Odds Ratio Proportion of patients treated with QA ACT among confirmed cases, by patient and provider/outlet factors All patients Type of outlet Private For-Profit Facility Drug Store Pharmacy Outlet location Urban area Rural area Patient sex Female Male Patient age+ 0-4 years 5-14 years years 50 years or older Reported fever symptoms to a provider during the consultation (prompted or unprompted) Reported fever Did not report fever Prior to the current visit for this illness: Sought treatment elsewhere for this illness Did not seek treatment elsewhere for this illness Received a malaria blood test Tested previously Not tested previously Received any medicine Treated previously Not treated previously N of Patients (95 CI) ( ) ref ( ) *** ( ) ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) ( ) ( ) ( ) ( ) ref ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) Page 39
41 Table 8: Factors associated with QA ACT treatment, among fever patients with confirmed malaria Treated with QA ACT Odds Ratio Received an antimalarial Treated previously Not treated previously Provider with recent malaria CM training # Trained provider Untrained provider Provider with correct first-line knowledge ## Provider with knowledge Provider without knowledge Provider who cites ACT as most effective ### Provider without knowledge Provider with knowledge Cost of QA ACT treatment ^ Median and above Below median price * p<0.05 ** p<0.01 ***p< ref ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) ( ) ( ) ref ( ) * ( ) ( ) # Provider reported receiving training, including pre-service training or stand-alone workshops, on malaria diagnosis/malaria RDTs/malaria microscopy and/or treatment on the national malaria treatment guidelines ## Provider correctly cited the national first-line treatment for uncomplicated malaria (AL) ### Provider named ACT as the most effective treatment for malaria in children under five and adults ^ Price for the least expensive QA AETD available at the outlet on the day of the survey. Price was calculated for one adult equivalent treatment dose, or price for the amount needed to treat a 60kg adult. A median was calculated across all outlets and outlets were classified as providing QA ACT that was median cost or above, or below median. Price for QA ACT was not available for 31 patients. Source: ACTwatch Fever CM Survey, Uganda, Page 40
42 Annex 1: ACTwatch Background ACTwatch is a multi-country research project implemented by PSI ( Standardized tools and approaches are employed to provide comparable data across countries and over time. Project countries include: Benin, Cambodia, the Democratic Republic of Congo, Kenya, Laos, Madagascar, Myanmar, Nigeria, Tanzania (currently mainland only, previous work in Zanzibar), Thailand, Uganda, Vietnam, Zambia. The project was launched in 2008 with funding from the Bill and Melinda Gates Foundation (BMGF), and is currently funded through 2016 by the BMGF, UNITAID, and DFID. ACTwatch is designed to provide timely, relevant, and high quality antimalarial market evidence. 1 The goal of providing this market evidence is to inform and monitor national and global policy, strategy, and funding decisions for improving malaria case management. ACTwatch is monitoring antimalarial markets in the context of policy shifts and investments in the scale-up of first-line ACT and blood testing using RDTs. This has included adaptation of project methods for the evaluation of the Affordable Medicines Facility malaria (AMFm) pilot. 2 Project scale-up in the Greater Mekong sub-region (GMS) in 2015 was designed to deliver key indicators for informing and monitoring strategies and policies for malaria elimination. The project implements a set of research tools designed to: 1) Provide a picture of the total market for malaria case management, including all providers carrying antimalarials and RDTs and providing case management services, the relative antimalarial market share for each provider type, the antimalarial supply chain, and price markups within the supply chain for antimalarials and RDTs. 2) Monitor the readiness of market components for appropriate malaria case management, including availability of antimalarials and malaria blood testing; consumer price of antimalarial treatment and malaria blood testing; and provider qualifications, training, and knowledge. 3) Monitor the performance of market components for appropriate malaria case management, including the relative market share for quality-assured ACT relative to other antimalarial medicines; the demand for appropriate malaria case management captured through consumer knowledge, attitudes, and fever treatment-seeking behavior; and the quality of provider service delivery measured against national policies, guidelines, and minimum standards. ACTwatch research tools for malaria market monitoring include: 1. Outlet surveys Outlet surveys entail collecting quantitative data from all outlets and providers with the potential to sell or distribute antimalarials and/or provide malaria blood testing. These include health facilities, community health workers, pharmacies, drug stores, retail outlets, market stalls, and mobile providers. A screening process identifies outlets that provide antimalarials and/or malaria blood testing. Among these eligible outlets, service providers are interviewed and all antimalarials and RDTs are audited. The audit collects information about each antimalarial and RDT in stock (e.g. brand name, drug active ingredients and strengths, manufacturer, etc.) and retailer reports on consumer price and sale/distribution volumes for each product. A representative sample of outlets is identified within target study domains such that findings from the outlet survey provide estimates of antimalarial and RDT availability, price, and relative market share across the entire market, as well as within key market channels. 3 1 Shewchuk T, O Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malaria Journal, 10: AMFm Independent Evaluation Team Independent evaluation of Phase 1 of the Affordable Medicines Facility malaria (AMFm), multicountry independent evaluation report: final report. Calverton, MD and London: ICF International and London School of Hygiene and Tropical Medicine. 3 O Connell KA, Poyer S, Solomon T, et al Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. Malaria Journal, 12: Page 41
43 From 2008 through 2014, ACTwatch conducted 35 national outlet surveys across the 10 project countries. 4 Reports are available at and peer-reviewed publications have appeared in Malaria Journal and The Lancet Supply chain studies Supply chain studies employ quantitative and qualitative research methods to effectively map the antimalarial supply chain in a given country. The supply chain is mapped from the antimalarial outlets (service delivery points) identified during an outlet survey to national importers and distributors with identification of all mid-level distributers in between. Retail prices are documented along the supply chain to facilitate calculation of commodity mark-ups. From 2008 through 2012, ACTwatch conducted 8 national supply chain studies. Reports are available at and a peer-reviewed publication has appeared in PLoS One Population-based surveys Population-based surveys are conducted among consumers to document fever treatment-seeking behavior. A representative sample of the target population (caregivers of children and/or adults according to burden and risk) is identified, and a screening tool is used to identify individuals who have recently experienced fever. The surveys investigate the extent to which health care was sought, as well as common sources of care received. Respondent reports of malaria blood testing and antimalarials acquired are documented and summarized. The survey includes measures of demographic and other individual, household/family, and community characteristics that can be used to develop consumer profiles and monitor equity in access to malaria case management. From 2008 through 2012, ACTwatch conducted 14 household surveys focused on fever treatment-seeking behavior. Reports are available at and a peer-reviewed publication has appeared in Malaria Journal Fever case management quality of care Fever case management quality of care is monitored using a set of research tools designed to measure aspects of the interaction between providers and clients. ACTwatch launched fever case management quality of care studies in 2015 in a subset of project countries. The following research tools were integrated into the outlet surveys in Cambodia and Uganda and were implemented among private-sector outlets providing malaria testing and treatment: Exit interviews conducted with target consumers immediately after receiving fever case management services in the private sector. A structured interview documented client reports about key aspects of service delivery, including malaria blood testing, test results, medicines recommended/prescribed and obtained, counseling, and costs of services and commodities received. Exit interviews were also used to measure client recall and comprehension of provider counseling, including instructions for completing prescribed drug regimens and client satisfaction with services provided. A consultation observation checklist was used to document aspects of the provider-client interaction in the private sector. A trained observer completed the checklist designed to document provider compliance with standard practice and procedures as well as aspects of client demand for specific products or services. The observer remained silent during the consultation. 4 Surveys in the DRC (2) and Myanmar (3) were sub-national. 5 O Connell K, Gatakaa H, Poyer S, et al Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malaria Journal, 10: 326. Tougher S, the ACTwatch Group, Ye Y, et al Effect of the Affordable Medicines Facility malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data. Lancet, 380: Palafox B, Patouillard E, Tougher S, et al Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries. PLoS One, 9(4). 7 Littrell M, Gatakaa H, Evance I, et al. (2011). Monitoring fever treatment behavior and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malaria Journal, 10: Page 42
44 ACTwatch in Uganda ACTwatch baseline surveys were conducted in Uganda in 2008 and 2009, followed by baseline and endline surveys for AMFm in 2010 and 2011, respectively. Additional surveys were conducted in 2013 and All reports are available at Page 43
45 Annex 2: Country Background Uganda is a landlocked country in East Africa bordered by Kenya, South Sudan, Rwanda, Tanzania, and the Democratic Republic of the Congo. Uganda has an estimated population of 36.6 million people, the majority of who live in rural areas 8. Uganda has made substantial progress in recent years toward attaining 2015 Millennium Development Goals (MDG). This progress has included early attainment of poverty-reduction targets, and strong progress toward targets for reducing hunger and under-nutrition and child morbidity and mortality 9. Despite incredible progress, mortality rates for children under five (69 per 1,000 live births) and infants (45 per 1,000 live births) remain high 10. Administratively, Uganda is divided into 112 districts. Districts are further sub-divided into sub-counties and parishes. Over time, the numbers of districts and lower-level administrative units have increased with the aim of making administration and delivery of social services easier and closer to the people 11. Since 1986, the government has acted to rehabilitate and stabilize the economy by undertaking currency reform, raising producer prices on export crops, increasing prices of petroleum products, and improving civil service wages. The policy changes are especially aimed at dampening inflation and boosting production and export earnings. Since 1990, economic reforms ushered in an era of solid economic growth based on continued investment in infrastructure, improved incentives for production and exports, lower inflation, better domestic security, and the return of exiled Indian-Ugandan entrepreneurs 12. From the mid-1980s to the 1990s, Gross Domestic Product (GDP) growth in Uganda averaged about 5.3 percent while the population only grew at about 3.2 percent annually. In the 2000s to 2014, GDP has increased to an average of 6.6 percent while average annual population growth has remained steady at around 3.3 percent. Additionally, per capita income increased from 180 USD in 1984 to 670 USD in Healthcare system The provision of health services in Uganda is decentralized, with districts and health sub-districts playing a key role in the delivery and management of health services at those levels. The government eliminated user fees in 2001, and services in public health facilities are thus free. User fees remain in place in private wings of public hospitals 14. The public sector is organized into the following health services: 1. Village Health Teams (VHTs) (Health Center I) Provide services at the community level. They facilitate and are responsible for health promotion, community mobilization to improve health-seeking behaviors, and treatment of diseases. After the adoption of integrated community case management in 2010, two out of five VHTs provide diagnosis and treatment. 2. Health Center II Provide diagnosis and maternity care and are the first referral point in the sub-county. 3. Health Center III In addition to providing basic preventative and curative care, Health Center IIIs provide support and supervision to Health Center IIs. 4. Health Center IV or General Hospitals These facilities provide oversight of all the other lower-level health facilities. General Hospitals often provide pre-service training and services related to prevention of diseases, blood transfusion, and medical imaging. 5. Regional Referral Hospitals These are often research and teaching hospitals and are involved in specialized services, such as medical imaging, psychiatry, and surgery. 8 Uganda Bureau of Statistics. (2014) Statistical abstract. Available: Accessed October 22, Ministry of Finance, Planning and Economic Development (2013). Millennium Development Goals report for Uganda Kampala: Ministry of Finance, Planning and Economic Development. 10 UNICEF. (2013). Uganda statistics. Available: Accessed October 22, Ministry of Health. (2010). Health sector strategic & investment plan. Kampala: Uganda Ministry of Health. 12 CIA World Fact Book (2015). Africa: Uganda. Accessed, December 12, World Bank (2015). Uganda Databank. Accessed, December 12, Ibid. Page 44
46 6. National Referral Hospital These are often research and teaching hospitals, and are involved in provision of specialized services. VHTs became part of Uganda s national health strategy in VHT volunteers serve as a community-based primary health contact with responsibilities, including identifying community health needs; mobilizing resources; mobilizing community participation for public health campaigns (e.g. immunization, sanitation, health-seeking behavior, malaria control); birth and death registration; and community-based management of common childhood illnesses, including malaria, diarrhea, and pneumonia. Four or five VHT volunteers are selected per village. The target of the Health Sector Strategic and Investment Plan is to increase VHT coverage to 100 percent by As of 2009, 31 percent of districts had trained VHTs in all villages 15. Uganda has a total of 155 hospitals there are two referral hospitals, 14 regional referral hospitals, and 139 general hospitals. Out of the 155 hospitals countrywide, 27 are privately owned 16. The medicines distribution system in the public sector is centralized with procurement, pooled at the national level and organized through the National Medical Stores, an agency of the Ministry of Health. Nearly all public-sector procurements are imported (94 percent) 17. The private not-for-profit sector is also important in Uganda for medicines delivery and treatment. These outlets include mission/faith-based hospitals and clinics. Faith-based/mission not-for-profit facilities account for 41 percent of hospitals and 22 percent of lower-level facilities complementing government facilities, especially in rural areas 18. The private sector The private sector plays a significant role in the health system in Uganda and is estimated to provide about half of health services in the country 19. The 2012 ACTwatch household survey in Uganda found that more than half of children with fever were taken to a private-sector outlet for treatment 20. Private-sector outlets in Uganda include for-profit hospitals and clinics. Health professionals working in these facilities commonly have an affiliation with government/public health services. About half of doctors working in the private sector also work in the government sector; however, more than 90 percent of the nurses, midwives, and nursing assistants working in the private sector work full-time in the private sector. Private for-profit facilities have a large urban and peri-urban presence and provide primary and secondary care. More than 90 percent of private for-profit facilities offer malaria treatment 21. The private for-profit sector in Uganda also includes pharmacies and drug stores (licensed and unlicensed). The pharmaceutical sector in Uganda is regulated by the National Drug Authority (NDA). Drug stores and pharmacies are licensed by the NDA, and NDA licensing fees for these outlets recently increased significantly 22. Pharmacies must be staffed by a registered pharmacist and may dispense prescription-only and over-the-counter (OTC) medicines. Licensed drug stores must be staffed by a provider with a health qualification (e.g. pharmacy technician, registered/enrolled nurse, clinical officer, etc.). Drug stores are permitted to retail a range of OTC medicines but are not authorized to sell prescription-only medicines. ACTs were classified as OTC medicines in The NDA monitors private outlets for the illegal sale of medicines, including medicine sales by unlicensed drug stores and sale of government-procured medicines and supplies found outside of public health facilities. The crackdown on outlets illegally selling medicines has been a topic frequently covered by national media Ibid. 16 Ministry of Health (2015). Affiliated Institutions: Hospitals. Accessed, November 2, Palafox B, Patoullard E, Tougher S, et al. (2012). ACTwatch 2009 supply chain survey results, Uganda. Nairobi: ACTwatch, PSI. 18 Ministry of Health. (2010). Health sector strategic & investment plan. Kampala: Uganda Ministry of Health. 19 Ibid. 20 ACTwatch Group and PACE. (2013). Household survey, Uganda, 2012 survey report. Washington DC: PSI. 21 Ministry of Health. (2010). Health sector strategic & investment plan. Kampala: Uganda Ministry of Health. 22 NDA doubles license fees for drug shop, pharmacies. (2013). Available: Accessed: October 22, Palafox B, Patoullard E, Tougher S, et al. (2012). ACTwatch 2009 supply chain survey results, Uganda. Nairobi: ACTwatch, PSI. 24 Personal communication, 2013 ACTwatch Key Informant Interviews, Uganda. Page 45
47 There are several local drug manufacturers in Uganda, including manufacturers of antimalarial medicines. In 2010, the Kampala manufacturing site for Quality Chemicals Industries Limited became Africa s first local supplier to receive WHO pre-qualification to produce ACTs. The company is licensed to produce artemether lumefantrine through the company Cipla Limited ( based in India. Although local manufacturers are present in Uganda, the majority (~90 percent) of pharmaceuticals are imported from Asian, Western, and other African countries (Kenya, South Africa). Results of a mapping exercise undertaken in 2008 estimated that percent of imported medicines in Uganda are generic products 25. Malaria risk and burden The climate of Uganda is tropical and tempered by altitude. In most parts of Uganda, temperature and rainfall allow intense perennial malaria transmission. Malaria is highly endemic across 95 percent of the country, affecting approximately 90 percent of the population (see national control program map in Figure X1). These areas include the entire Central region and the majority of the Northern and Southern regions. Particularly high transmission rates have been documented in some areas of northern Uganda, where prior to indoor residual spray campaigns, entomological inoculation rates were documented as high as 1,600 infective bites per person per year. The 5 percent of the country (10 percent of the population) that does not have endemic malaria consists of unstable and epidemic-prone transmission areas in the highlands of the South and Mid-west, along the eastern border with Kenya, and the northeastern border with Sudan 26. Malaria continues to be a major public health problem in Uganda and is the leading cause of morbidity and mortality among children younger than age five 27. The most recent national Malaria Indicator Survey (MIS) indicated that malaria was responsible for 30 to 50 percent of outpatient hospital visits, and 9 to 14 percent of inpatient deaths in The latest MIS report also documented a parasite prevalence of 19 percent among all children younger than five when testing with microscopy. Most malaria infections in Uganda are due to Plasmodium falciparum 29. Figure X1. Map of malaria endemicity Source: PMI FY2014 Malaria Operational Plan. Malaria case management guidelines The revised Uganda Malaria Reduction Strategic Plan (UMRSP) primary targets are to reduce malaria deaths to near zero, reduce malaria morbidity to 30 cases per 1,000 persons, and to reduce malaria parasite 25 UMOH (2008). Cited in Medicines Transparency (medicinestransparency.org): The role of local manufacturers in improving access to essential medicine (2010). Accessed May 6, 2016: Uganda_AfricaHealth.pdf 26 Uganda Bureau of Statistics (UBOS) and ICF Macro. (2010). Uganda malaria indicator survey Calverton, MD: UBOS and ICF Macro. 27 Uganda Bureau of Statistics. (2014) Statistical abstract. Available: Accessed October 22, Uganda Ministry of Health. (2015). Malaria indicator survey, Retrieved from: 29 Uganda Bureau of Statistics (2016). The National Population and Housing Census 2014 Main Report, Kampala, Uganda Ibid. Page 46
PROGRAM BRIEF UGANDA. Integrated Case Management of Pneumonia, Diarrhea & Malaria through the Five & Alive Franchise Network
PROGRAM BRIEF UGANDA Integrated Case Management of Pneumonia, Diarrhea & Malaria through the Five & Alive Franchise Network I ntegrated case management (ICM) is a strategy to reduce child morbidity and
More informationDownloaded from:
Mbonye, AK; Buregyeya, E; Rutebemberwa, E; Clarke, SE; Lal, S; Hansen, KS; Magnussen, P; LaRussa, P (2016) Prescription for antibiotics at drug shops and strategies to improve quality of care and patient
More informationUSE OF A PRIVATE SECTOR CO-PAYMENT MECHANISM TO IMPROVE ACCESS TO ACTs IN THE NEW FUNDING MODEL INFORMATION NOTE
USE OF A PRIVATE SECTOR CO-PAYMENT MECHANISM TO IMPROVE ACCESS TO ACTs IN THE NEW FUNDING MODEL INFORMATION NOTE Introduction In November 2012, the Global Fund Board decided to integrate the lessons learned
More informationInterventions to Improve Providers Ability to Diagnose and Treat Uncomplicated Malaria: A Literature Review
Interventions to Improve Providers Ability to Diagnose and Treat Uncomplicated Malaria: A Literature Review Prepared by Lindsay Mangham, Department of Public Health and Policy, London School of Hygiene
More informationStandard operating procedures for the conduct of outreach training and supportive supervision
The MalariaCare Toolkit Tools for maintaining high-quality malaria case management services Standard operating procedures for the conduct of outreach training and supportive supervision Download all the
More informationPMI Quarterly Status Report April 2011 June 2011
PMI Quarterly Status Report April 2011 June 2011 Submitted by: The Johns Hopkins Bloomberg School of Public Health Center for Communication Programs & Uganda Health Marketing Group - UHMG ACRONYMS ACT
More informationIntroducing rapid diagnostic tests for malaria into drug shops in Uganda: design and implementation of a cluster randomized trial
Mbonye et al. Trials 2014, 15:303 TRIALS RESEARCH Open Access Introducing rapid diagnostic tests for malaria into drug shops in Uganda: design and implementation of a cluster randomized trial Anthony K
More informationAFFORDABLE MEDICINES FACILITY MALARIA
AFFORDABLE MEDICINES FACILITY MALARIA Frequently Asked Questions Outline Introduction to AMFm AMFm Phase 1 AMFm Phase 1 Applications Implementing Phase 1 Funding AMFm Phase 1 How to order co-paid ACTs
More informationEvaluation of the Quality of Community Based Integrated Management of Childhood Illness and Reproductive Health Programs in Madagascar
Evaluation of the Quality of Community Based Integrated Management of Childhood Illness and Reproductive Health Programs in Madagascar FEBRUARY 2013 This evaluation report was produced by University Research
More informationSuccessful Practices to Increase Intermittent Preventive Treatment in Ghana
Successful Practices to Increase Intermittent Preventive Treatment in Ghana Introduction The devastating consequences of Plasmodium falciparum malaria in pregnancy (MIP) are welldocumented, including higher
More informationAffordable Medicines Facility - malaria
Affordable Medicines Facility - malaria Antimalarial Treatment Strategies Conference 31 March 3 April 2008 History of the Affordable Medicines Facility malaria project 2004 2007 2008 RBM leads a Partnership
More informationTRIALS. Wiseman et al. Trials 2012, 13:81
Wiseman et al. Trials 2012, 13:81 TRIALS STUDY PROTOCOL Open Access A cost-effectiveness analysis of provider and community interventions to improve the treatment of uncomplicated malaria in Nigeria: study
More informationAssessment of communication and clinical skills of community health workers in rural Uganda. Dr. James Ssekitoleeko 30 th May 2013
Assessment of communication and clinical skills of community health workers in rural Uganda Dr. James Ssekitoleeko 30 th May 2013 Outline Background Objective of the study Methodology Results Learning
More informationOutlet Survey Republic of Benin 2009 Survey Report
Evidence for Malaria Medicines Policy Outlet Survey Republic of Benin 2009 Survey Report Country Program Coordinator Cyprien Zinsou Association Béninoise pour le Marketing Social/PSI Lot 919 Immeuble Montcho
More informationStandard operating procedures: Health facility malaria committees
The MalariaCare Toolkit Tools for maintaining high-quality malaria case management services Standard operating procedures: Health facility malaria committees Download all the MalariaCare Tools from: www.malariacare.org/resources/toolkit
More informationDownloaded from:
Mangham-Jefferies, L; Hanson, K; Mbacham, W; Onwujekwe, O; Wiseman, V (2014) Mind the gap: knowledge and practice of providers treating uncomplicated malaria at public and mission health facilities, pharmacies
More informationNATIONAL DEPARTMENT OF HEALTH. National Malaria Control Program Strategic Plan
NATIONAL DEPARTMENT OF HEALTH National Malaria Control Program Strategic Plan 2009 2013 TABLE OF CONTENTS FORWARD ACKNOWLEDGEMENTS ABBREVIATIONS AND ACRONYMS INTRODUCTION Malaria remains one of the largest
More informationSupportive supervision checklist on IMCI
Supportive supervision checklist on IMCI Name of the health centre: Sub-district/municipality/Zone: District: Date of supervision:.../.../... Name of Supervisor: Designation: 1. Health services organisation
More informationQUALITY OF MALARIA CASE MANAGEMENT IN ZAMBIA, 2011 A DISSERTATION SUBMITTED ON THE TWENTY-FIRST DAY OF NOVEMBER 2016
QUALITY OF MALARIA CASE MANAGEMENT IN ZAMBIA, 2011 A DISSERTATION SUBMITTED ON THE TWENTY-FIRST DAY OF NOVEMBER 2016 TO THE DEPARTMENT OF GLOBAL HEALTH MANAGEMENT AND POLICY IN PARTIAL FULFILLMENT OF THE
More informationAnnual Pharmaceutical Sector Performance Report
Ministry of Health Republic of Uganda Annual Pharmaceutical Sector Performance Report 2014-2015 June 2016 FOREWORD The Annual Pharmaceutical Sector Performance Report provides us with a valuable picture
More informationChanging Malaria Treatment Policy to Artemisinin-Based Combinations
Changing Malaria Treatment Policy to Artemisinin-Based Combinations An Implementation Guide Developed by the Rational Pharmaceutical Management Plus Program in collaboration with the Roll Back Malaria
More informationImproving Malaria Case Management in Ghana
GHANA December, 2016 Edition Message from the Programme Manager, NMCP Improving Malaria Case Management in Ghana Maintaining Healthcare Workers' Skills and Knowledge through Quality Assurance Processes
More informationTHE UGANDA STOP MALARIA PROJECT YEAR 6 WORK PLAN. October 1, 2013 September 30, USAID/JHU Cooperative Agreement No. CA 617-A
THE UGANDA STOP MALARIA PROJECT YEAR 6 WORK PLAN October 1, 2013 September 30, 2014 USAID/JHU Cooperative Agreement No. CA 617-A-00-08-00018-00 Re-Submitted 08 October 2013 Johns Hopkins Bloomberg School
More informationDownloaded from:
Kangwana, BP; Kedenge, SV; Noor, AM; Alegana, VA; Nyandigisi, AJ; Pandit, J; Fegan, GW; Todd, JE; Brooker, S; Snow, RW; Goodman, CA (2011) The Impact of Retail-Sector Delivery of Artemether- Lumefantrine
More informationThis Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national
This Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national malaria control programs and partners in country. The final
More informationSIAPS Liberia Final Report
SIAPS Liberia Final Report September 2011 September 2013 SIAPS Liberia Final Report This report is made possible by the generous support of the American people through the US Agency for International Development
More informationStop Malaria Project. Health Facility Assessment Survey Report
Stop Malaria Project Health Facility Assessment Survey Report September 2011 USAID/JHU Cooperative Agreement No. CA 617-A-00-08-00018-00 1 Table of Contents LIST OF ACRONYMS AND ABBREVIATIONS... 4 EXECUTIVE
More informationIncreasing Access to Subsidized Artemisininbased Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania
RESEARCH Open Access Increasing Access to Subsidized Artemisininbased Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania Edmund Rutta 1*, Bryceson Kibassa 2, Brittany McKinnon 3,
More informationRWANDA S COMMUNITY HEALTH WORKER PROGRAM r
RWANDA S COMMUNITY HEALTH WORKER PROGRAM r Summary Background The Rwanda CHW Program was established in 1995, aiming at increasing uptake of essential maternal and child clinical services through education
More informationBMC Partners Meeting. Ghana BMC project Progress Geneva 22 November, 2011
BMC Partners Meeting Ghana BMC project Progress Geneva 22 November, 2011 Introduction The Better Medicines for Children (BMC) Project funded by the Bill and Melinda Gates Foundation aims to improve access
More informationTHE UGANDA STOP MALARIA PROJECT YEAR 5 WORK PLAN
THE UGANDA STOP MALARIA PROJECT YEAR 5 WORK PLAN October 1, 2012 September 30, 2013 USAID/JHU Cooperative Agreement No. CA 617-A-00-08-00018-00 Re-Submitted 27 September 2012 Johns Hopkins Bloomberg School
More informationDownloaded from:
Bruxvoort, K; Kalolella, A; Cairns, M; Festo, C; Kenani, M; Lyaruu, P; Kachur, SP; Schellenberg, D; Goodman, C (2015) Are Tanzanian patients attending public facilities or private retailers more likely
More informationIDENTIFYING AND MOVING LEVERS
IDENTIFYING AND MOVING LEVERS OF ACCEPTANCE AND UPTAKE OF RECOMMENDED QUALITY-ASSURED PAEDIATRIC ACTS FOR NONCOMPLICATED MALARIA IN SIX FRANCOPHONE AFRICA COUNTRIES Dr Florence Camus-Bablon November 2012
More informationThis Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national
This Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national malaria control programs and partners in country. The final
More informationThis Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national
This Malaria Operational Plan has been approved by the U.S. Global Malaria Coordinator and reflects collaborative discussions with the national malaria control programs and partners in country. The final
More informationNational Patient Safety Foundation at the AMA
National Patient Safety Foundation at the AMA National Patient Safety Foundation at the AMA Public Opinion of Patient Safety Issues Research Findings Prepared for: National Patient Safety Foundation at
More informationAppendix. We used matched-pair cluster-randomization to assign the. twenty-eight towns to intervention and control. Each cluster,
Yip W, Powell-Jackson T, Chen W, Hu M, Fe E, Hu M, et al. Capitation combined with payfor-performance improves antibiotic prescribing practices in rural China. Health Aff (Millwood). 2014;33(3). Published
More informationEngaging the Private Retail Pharmaceutical Sector in TB Case Finding in Tanzania: Pilot Dissemination Meeting Report
Engaging the Private Retail Pharmaceutical Sector in TB Case Finding in Tanzania: Pilot Dissemination Meeting Report February 2014 Engaging the Private Retail Pharmaceutical Sector in TB Case Finding
More informationPreliminary Results of Antibiotic Utilization Studies Using Point Prevalence Survey In Botswana
Preliminary Results of Antibiotic Utilization Studies Using Point Prevalence Survey In Botswana Bene D Anand Paramadhas, Joyce Kgatlwane, Celda Tiroyakgosi, Matshediso Matome, Amos Massele, Jaran Eriksen,
More informationADDRESSING CHALLENGES TO ANTIMALARIAL ACCESS AND MALARIA CASE MANAGEMENT. 7 & 8 December, Addis Ababa, Ethiopia
ADDRESSING CHALLENGES TO ANTIMALARIAL ACCESS AND MALARIA CASE MANAGEMENT 7 & 8 December, Addis Ababa, Ethiopia Contents Introduction 5 Procurement and supply management 6 Scaling up access to malaria diagnostics
More informationSources for Sick Child Care in India
Sources for Sick Child Care in India Jessica Scranton The private sector is the dominant source of care in India. Understanding if and where sick children are taken for care is critical to improve case
More informationService Provision Assessment (SPA) Surveys
Service Provision Assessment (SPA) Surveys Overview of Methodology, Key MNH Indicators and Service Readiness Indicators Paul Ametepi, MEASURE DHS 01/14/2013 Outline of presentation Overview of SPA methodology
More information2016 National NHS staff survey. Results from Wirral University Teaching Hospital NHS Foundation Trust
2016 National NHS staff survey Results from Wirral University Teaching Hospital NHS Foundation Trust Table of Contents 1: Introduction to this report 3 2: Overall indicator of staff engagement for Wirral
More informationNational Performance Report on Medicines Management. The fourth National Performance Report on medicines management is here.
This report covers the period from: Issue no. 4 January 2015 through March 2015 Tuesday, April 21, 2015 Published by: Data source: MMS data version 4.0 P.O. Box 7272 Executive Summary National Performance
More informationFinal: REPORT OF THE IMCI HEALTH FACILITY SURVEY IN BOTSWANA
REPORT OF THE IMCI HEALTH FACILITY SURVEY IN BOTSWANA 1 TABLE OF CONTENTS ABBREVIATIONS 3 EXECUTIVE SUMMARY 4 Background 4 Methods 4 Results 4 Recommendations 5 1. BACKGROUND 6 1.1 Child Health in Botswana
More informationINTRODUCTION. KEY ACHIEVEMENTS Malaria
Redacted INTRODUCTION Although important achievements have been realized in maternal, newborn, and child health (MNCH) in Rwanda, there is still a need for improvement. The maternal mortality rate decreased
More informationPMM. June Revised Edition Rational Pharmaceutical Management Plus Program USAID Cooperative Agreement Number: HRN-A
Pharmaceutical Management for Malaria PMM PHARMACEUTICAL MANAGEMENT FOR MALARIA MANUAL June 2000 Revised Edition 2004 Rational Pharmaceutical Management Plus Program USAID Cooperative Agreement Number:
More informationAdherence to malaria diagnosis and treatment guidelines among healthcare workers in Ogun State, Nigeria
Bamiselu et al. BMC Public Health (2016) 16:828 DOI 10.1186/s12889-016-3495-x RESEARCH ARTICLE Adherence to malaria diagnosis and treatment guidelines among healthcare workers in Ogun State, Nigeria Oluyomi
More informationReport of the Evaluation of the USAID/Uganda Stop Malaria Project
Report of the Evaluation of the USAID/Uganda Stop Malaria Project Submitted to: Zdenek Suda, Program Officer, USAID/Uganda By Robert Pond, Fred Matovu and Festus Kibuuka October 2013 Report of the final
More informationSIAPS/PMI - AMDM Scale-Up Sites Baseline Assessment. Hailu Tegegnework and Fikadu Deme
SIAPS/PMI - AMDM Scale-Up Sites Baseline Assessment Hailu Tegegnework and Fikadu Deme August 24 SIAPS/PMI - AMDM Scale-Up Sites Baseline Assessment This technical report is made possible by the generous
More informationReport of the Tanzania Assessment of Community Services for Childhood Illness. Final December 12, 2012
Report of the Tanzania Assessment of Community Services for Childhood Illness Final December 12, 2012 1 Table of Contents ACKNOWLEDGEMENTS 4 LIST OF ACRONYMS 5 EXECUTIVE SUMMARY 6 BACKGROUND 13 IMCI training
More informationTranslating an Idea into a Policy: Saving Lives and Buying Time for Antimalarial Medicines
Global Health Teaching Case From the Harvard School of Public Health Translating an Idea into a Policy: Saving Lives and Buying Time for Antimalarial Medicines PART A This case was written by Laura Frost,
More informationPolicy Guidelines and Service Delivery Standards for Community Based Provision of Injectable Contraception in Uganda
Policy and Service Delivery Standards for Community Based Provision of Injectable Contraception in Uganda Addendum to Uganda National Policy and Service Standards for Sexual and Reproductive Health December
More information34th Board Meeting Mid-year 2015 Corporate KPI Results & 2016 Targets For Board Decision
34th Board Meeting Mid-year 2015 Corporate KPI Results & 2016 For Board Decision GF/B34/08 Geneva, Switzerland 16-17 November 2015 Context For review Performance assessment for 13 indicators Strong performance
More informationDRC. Integrated Community Case Management of Pneumonia, Malaria & Diarrhea PROGRAM BRIEF
GR EF DRC Integrated Community Case Management of Pneumonia, Malaria & Diarrhea I ntegrated community case management (iccm) is a strategy to improve coverage of case management for the top killers of
More informationOnline Classifieds. The number of online adults to use classified ads websites, such as Craigslist, more than doubled from 2005 to 2009.
Online Classifieds The number of online adults to use classified ads websites, such as Craigslist, more than doubled from 2005 to 2009. May 2009 Sydney Jones Research Assistant View Report Online: http://pewinternet.org/reports/2009/7--online-classifieds.aspx
More informationCLINICAL AUDIT. The laboratory investigation of. UTI in females. in primary care
CLINICAL AUDIT The laboratory investigation of UTI in females in primary care Valid to December 2018 bpac nz better medicin e Background Approximately 50% of all females will have a urinary tract infection
More informationChecklist for assessing rapid diagnostic test use
The MalariaCare Toolkit Tools for maintaining high-quality malaria case management services Checklist for assessing rapid diagnostic test use This checklist was developed by the MalariaCare project for
More informationREVIEW OF MONITORING OF MALARIA IN PREGNANCY THROUGH NATIONAL HEALTH MANAGEMENT INFORMATION SYSTEMS: MALAWI
REVIEW OF MONITORING OF MALARIA IN PREGNANCY THROUGH NATIONAL HEALTH MANAGEMENT INFORMATION SYSTEMS: MALAWI April 2014 Chimwemwe Msukwa Barbara Rawlins Mary Drake The findings of this review are based
More informationPatient survey report Survey of people who use community mental health services Boroughs Partnership NHS Foundation Trust
Patient survey report 2013 Survey of people who use community mental health services 2013 The survey of people who use community mental health services 2013 was designed, developed and co-ordinated by
More informationA Concept note and Terms of Reference on Assessment of Community-Based Integrated Management of Neonatal and Childhood Illness (CB-IMNCI) Program
A Concept note and Terms of Reference on Assessment of Community-Based Integrated Management of Neonatal and Childhood Illness (CB-IMNCI) Program Background Nepal has a long history of implementation of
More informationPatient Pathway Analysis: How-to Guide. Assessing the Alignment of TB Patient Care Seeking & TB Service Delivery
Patient Pathway Analysis: How-to Guide Assessing the Alignment of TB Patient Care Seeking & TB Service Delivery Table of Contents Acknowledgments... 5 Acronyms... 6 INTRODUCTION 7 0.1 Background... 7
More informationTHE UGANDA STOP MALARIA PROJECT ANNUAL PERFORMANCE REPORT
THE UGANDA STOP MALARIA PROJECT ANNUAL PERFORMANCE REPORT OCTOBER 1 ST SEPTEMBER 30 TH 2014 Submitted to USAID on October 30 th, 2014 USAID/JHU Cooperative Agreement No. CA 617-A-00-08-00018-00 1 Table
More informationFACTORS INFLUENCING MALARIA TREATMENT AND PATIENT ADHERENCE TO ANTIMALARIAL DRUGS IN SOUTHERN ETHIOPIA
FACTORS INFLUENCING MALARIA TREATMENT AND PATIENT ADHERENCE TO ANTIMALARIAL DRUGS IN SOUTHERN ETHIOPIA K.D. Gidebo, D Litt et Phil Wolaita Sodo University T.R. Mavundla, D Cur, RN University of South Africa
More informationMalaria surveillance, monitoring and evaluation manual
Malaria surveillance, monitoring and evaluation manual Abdisalan M Noor, Team Leader, Surveillance Malaria Policy Advisory Committee (MPAC) meeting 22-24 March 2017, Geneva, Switzerland Global Technical
More informationSystematic Engagement of Hospitals Philippine Experience. Dr. Marl Mantala 8 th PPM Sub-group Meeting, 10 Nov. 2012, Kuala Lumpur
Systematic Engagement of Hospitals Philippine Experience Dr. Marl Mantala 8 th PPM Sub-group Meeting, 10 Nov. 2012, Kuala Lumpur Flow of discussion Context Process Results Recommendations Philippines Population:
More informationTHE UGANDA STOP MALARIA PROJECT YEAR 7 WORK PLAN. September 30, March 27, USAID/JHU Cooperative Agreement No. CA 617-A
THE UGANDA STOP MALARIA PROJECT YEAR 7 WORK PLAN September 30, 2014- March 27, 2015 USAID/JHU Cooperative Agreement No. CA 617-A-00-08-00018-00 Submitted 28 November 2014 Johns Hopkins Bloomberg School
More informationGlobal Fund Grants for Malaria: Lessons Learned in the Implementation of ACT Policies in Nigeria
Global Fund Grants for Malaria: Lessons Learned in the Implementation of ACT Policies in Nigeria Rima Shretta Catherine Adegoke Peter Segbor June 2007 Rational Pharmaceutical Management Plus Center for
More informationDownloaded from:
Webster, J; Baiden, F; Bawah, J; Bruce, J; Tivura, M; Delmini, R; Amenga-Etego, S; Chandramohan, D; Owusu-Agyei, S (2014) Management of febrile children under five years in hospitals and health centres
More informationSCHOOL OF PUBLIC HEALTH COLLEGE OF HEALTH SCIENCES UNIVERSITY OF GHANA FACTORS INFLUENCING COMPLIANCE OF PRESCRIBERS WITH MALARIA TEST-
SCHOOL OF PUBLIC HEALTH COLLEGE OF HEALTH SCIENCES UNIVERSITY OF GHANA FACTORS INFLUENCING COMPLIANCE OF PRESCRIBERS WITH MALARIA TEST- BASED CASE MANAGEMENT POLICY IN EFFUTU MUNICIPALITY. BY ALEXANDER
More informationBCBSM Physician Group Incentive Program
BCBSM Physician Group Incentive Program Organized Systems of Care Initiatives Interpretive Guidelines 2012-2013 V. 4.0 Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee
More informationSection 6: Referral record headings
Section 6: Referral record headings Referral record standards: the referral headings are primarily intended for recording the clinical information in referral communication between general practitioners
More informationCOUNTRY PROFILE: LIBERIA LIBERIA COMMUNITY HEALTH PROGRAMS JANUARY 2014
COUNTRY PROFILE: LIBERIA JANUARY 2014 Advancing Partners & Communities Advancing Partners & Communities (APC) is a five-year cooperative agreement funded by the U.S. Agency for International Development
More informationManagement of Childhood Illness at Health Facilities in Benin: Problems and Their Causes
Management of Childhood Illness at Health Facilities in Benin: Problems and Their Causes Alexander K. Rowe, MD, MPH, Faustin Onikpo, MD, MPH, Marcel Lama, MD, MPH, Francois Cokou, ITS, and Michael S. Deming,
More informationEgypt, Arab Rep. - Demographic and Health Survey 2008
Microdata Library Egypt, Arab Rep. - Demographic and Health Survey 2008 Ministry of Health (MOH) and implemented by El-Zanaty and Associates Report generated on: June 16, 2017 Visit our data catalog at:
More information2016 National NHS staff survey. Results from Surrey And Sussex Healthcare NHS Trust
2016 National NHS staff survey Results from Surrey And Sussex Healthcare NHS Trust Table of Contents 1: Introduction to this report 3 2: Overall indicator of staff engagement for Surrey And Sussex Healthcare
More informationUNICEF WCARO October 2012
UNICEF WCARO October 2012 Case Study on Narrowing the Gaps for Equity Benin Equity in access to health care for the most vulnerable children through Performance- based Financing of Community Health Workers
More informationAccess to Health Care Services in Canada, 2003
Access to Health Care Services in Canada, 2003 by Claudia Sanmartin, François Gendron, Jean-Marie Berthelot and Kellie Murphy Health Analysis and Measurement Group Statistics Canada Statistics Canada Health
More informationHelping Providers Diagnose and Treat Malaria in Pregnancy: MIP Case Management Job Aid
Helping Providers Diagnose and Treat Malaria in Pregnancy: MIP Case Management Job Aid Patricia P. Gomez Sr. Technical Advisor for Maternal and Newborn Health 21 February 2017 Presentation Outline Discuss
More information2017 National NHS staff survey. Results from The Newcastle Upon Tyne Hospitals NHS Foundation Trust
2017 National NHS staff survey Results from The Newcastle Upon Tyne Hospitals NHS Foundation Trust Table of Contents 1: Introduction to this report 3 2: Overall indicator of staff engagement for The Newcastle
More informationPILOT COHORT EVENT MONITORING OF ACTS IN NIGERIA
* NATIONAL AGENCY FOR FOOD AND DRUG * PILOT COHORT EVENT MONITORING OF ACTS IN NIGERIA C. K. SUKU NATIONAL PHARMACOVIGILANCE CENTRE, NAFDAC, NIGERIA ANTIRETROVIRAL PHARMACOVIGILANCE COURSE DAR ES SALAAM,
More informationAbbreviations and Acronyms
Abbreviations and Acronyms ACT ANC AOTR BCC DHT HBMF HCU HMIS HW ICCM ID IPT LLIN MCP M&E MOH MOU NMCP PCV PMI PMP SP STAR SW UHC UMEMS USAID VHT VSLA Artemisinin-based Combination Therapy Antenatal Care
More information2017 National NHS staff survey. Results from Royal Cornwall Hospitals NHS Trust
2017 National NHS staff survey Results from Royal Cornwall Hospitals NHS Trust Table of Contents 1: Introduction to this report 3 2: Overall indicator of staff engagement for Royal Cornwall Hospitals NHS
More informationMEASURE DHS SERVICE PROVISION ASSESSMENT SURVEY HEALTH WORKER INTERVIEW
06/01/01 MEASURE DHS SERVICE PROVISION ASSESSMENT SURVEY HEALTH WORKER INTERVIEW Facility Number: Interviewer Code: Provider SERIAL Number: [FROM STAFF LISTING FORM] Provider Sex: (1=MALE; =FEMALE) Provider
More information1. Guidance notes. Social care (Adults, England) Knowledge set for medication. What are knowledge sets? Why were knowledge sets commissioned?
Social care (Adults, England) Knowledge set for medication 1. Guidance notes What are knowledge sets? Part of the sector skills council Skills for Care and Development Knowledge sets are sets of key learning
More information2017 National NHS staff survey. Results from Dorset County Hospital NHS Foundation Trust
2017 National NHS staff survey Results from Dorset County Hospital NHS Foundation Trust Table of Contents 1: Introduction to this report 3 2: Overall indicator of staff engagement for Dorset County Hospital
More informationO.M.S. Minzi 1 & A.F. Haule 2
117 POOR KNOWLEDGE ON NEW MALARIA TREATMENT GUIDELINES AMONG DRUG DISPENSERS IN PRIVATE PHARMACIES IN TANZANIA: THE NEED FOR INVOLVING THE PRIVATE SECTOR IN POLICY PREPARATIONS AND IMPLEMENTATION Abstract
More informationChallenges with changing prescribing practices from CQ/SP to ACT in the private sector
Challenges with changing prescribing practices from CQ/SP to ACT in the private sector A presentation at MMV Access Symposium Getting Antimalarials to Patients Kampala 9 th May 2007 Compiled by Dr James
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:
More informationInpatient Experience Survey 2016 Results for Royal Infirmary of Edinburgh
Results for August, Official Statistics Contents Page Introduction 3 Notes of interpretation 4 Chapter 1: Rated results 6 Chapter 2: Comparison with previous surveys 28 Chapter 3: Variation in hospital
More informationInpatient Experience Survey 2016 Results for Western General Hospital, Edinburgh
Results for, Edinburgh August, Official Statistics Contents Page Introduction 3 Notes of interpretation 4 Chapter 1: Rated results 6 Chapter 2: Comparison with previous surveys 28 Chapter 3: Variation
More informationCONCEPT NOTE MALARIA
SUMMARY INFORMATION Applicant Information Country Cameroon Component MALARIA Funding Start Date CONCEPT NOTE Request January 2015 Funding Request End Date December 2017 Principal Recipient(s) MALARIA Funding
More informationUSAID s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program ( )
USAID s Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program (2011-2016) IR* 1: Pharmaceutical sector governance strengthened 1.1 Good governance principles embodied across all health
More informationADHERENCE TO ANTIMALARIAL COMBINATION THERAPY WITH ARTEMETHER- LUMEFANTRINE IN CHILDREN BELOW FIVE YEARS IN EMBU DISTRICT, KENYA
ADHERENCE TO ANTIMALARIAL COMBINATION THERAPY WITH ARTEMETHER- LUMEFANTRINE IN CHILDREN BELOW FIVE YEARS IN EMBU DISTRICT, KENYA ELIJAH NJERU MBITI (BScN) A RESEARCH THESIS SUBMITTED FOR THE DEGREE OF
More informationREVIEW OF MONITORING OF MALARIA IN PREGNANCY THROUGH NATIONAL HEALTH MANAGEMENT INFORMATION SYSTEMS: KENYA
REVIEW OF MONITORING OF MALARIA IN PREGNANCY THROUGH NATIONAL HEALTH MANAGEMENT INFORMATION SYSTEMS: KENYA April 2014 Barbara Rawlins Augustine Ngindu Sanyu Kigondu The findings of this review are based
More informationExpanding Access to Injectables in Uganda: Winding Road in Going to Scale Angela Akol, FHI 360 / Uganda
Expanding Access to Injectables in Uganda: Winding Road in Going to Scale Angela Akol, FHI 360 / Uganda March 13, 2012, Washington, DC PROGRESS Technical Meeting, Institutionalizing Evidence-Based Practices
More informationPrimary Care Measures at the Sub-Region Level
Primary Care Measures at the Sub-Region Level Trillium Primary Health Care Research Day May 31, 2017 Paul Huras South East LHIN Overview The LHIN Mandate Primary Care Capacity Framework The South East
More informationPrescriber/Patient Enrollment Form MS Completion of all pages is required.
Date of birth: Patient name: Street address: / / (MM/DD/YYYY) City State ZIP Work telephone - - Home telephone - - Patient SSN - - Please attach copies of both sides of patient's insurance and pharmacy
More information1) What type of personnel need to be a part of this assessment team? (2 min)
Student Guide Module 2: Preventive Medicine in Humanitarian Emergencies Civil War Scenario Problem based learning exercise objectives Identify the key elements for the assessment of a population following
More informationStrategies to Improve the Use of Medicines Standard Treatment Guidelines
Strategies to Improve the Use of Medicines Standard Treatment Guidelines Review of the Cesarean-section Antibiotic Prophylaxis Program in Jordan and Workshop on Rational Medicine Use and Infection Control
More information